1. Science, P.s.C.o.A.o. and Technology, Report to the president on combating antibiotic resistance. 2014: Executive Office of the President, President's Council of Advisors on ….
2. Brown, E.D. and G.D. Wright, Antibacterial drug discovery in the resistance era. Nature, 2016. 529(7586): p. 336-343. [
DOI:10.1038/nature17042] [
PMID]
3. Control, C.f.D. and Prevention, Antibiotic resistance threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. 2020.
4. Rudd, K.E., et al., Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. The Lancet, 2020. 395(10219): p. 200-211. [
DOI:10.1016/S0140-6736(19)32989-7] [
PMID]
5. RP, D., Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med, 2004. 32: p. 858-873. [
DOI:10.1097/01.CCM.0000117317.18092.E4] [
PMID]
6. Rivers, E., et al., Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England journal of medicine, 2001. 345(19): p. 1368-1377. [
DOI:10.1056/NEJMoa010307] [
PMID]
7. Seymour, C.W., et al., Time to treatment and mortality during mandated emergency care for sepsis. New England Journal of Medicine, 2017. 376(23): p. 2235-2244. [
DOI:10.1056/NEJMoa1703058] [
PMID] [
]
8. Rhee, C., et al., Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. Jama, 2017. 318(13): p. 1241-1249. [
DOI:10.1001/jama.2017.13836] [
PMID] [
]
9. Rhee, C., et al., Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals. JAMA network open, 2019. 2(2): p. e187571-e187571. [
DOI:10.1001/jamanetworkopen.2018.7571] [
PMID] [
]
10. Riedel, S. and K.C. Carroll, Early identification and treatment of pathogens in sepsis: molecular diagnostics and antibiotic choice. Clinics in chest medicine, 2016. 37(2): p. 191-207. [
DOI:10.1016/j.ccm.2016.01.018] [
PMID]
11. Buehler, S.S., et al., Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clinical microbiology reviews, 2016. 29(1): p. 59-103. [
DOI:10.1128/CMR.00053-14] [
PMID] [
]
12. Torio, C.M. and B.J. Moore, National inpatient hospital costs: the most expensive conditions by payer, 2013. 2016.
13. Tamma, P.D., et al., Association of adverse events with antibiotic use in hospitalized patients. JAMA internal medicine, 2017. 177(9): p. 1308-1315. [
DOI:10.1001/jamainternmed.2017.1938] [
PMID] [
]
14. Caraballo, C. and F. Jaimes, Organ dysfunction in sepsis: an ominous trajectory from infection to death. The Yale journal of biology and medicine, 2019. 92(4): p. 629.
15. Cordioli, R.L., et al., Sepsis and pregnancy: do we know how to treat this situation? Revista Brasileira de terapia intensiva, 2013. 25(4): p. 334-344. [
DOI:10.5935/0103-507X.20130056] [
PMID] [
]
16. Hotchkiss, R.S., et al., Sepsis and septic shock. Nat Rev Dis Primers, 2016. 2: p. 16045. [
DOI:10.1038/nrdp.2016.45] [
PMID] [
]
17. Wall, L.L. and A. Yemane, Infectious Complications of Abortion. Open Forum Infect Dis, 2022. 9(11): p. ofac553. [
DOI:10.1093/ofid/ofac553] [
PMID] [
]
18. Pados, G., et al., Adenomyosis and Infertility: A Literature Review. Medicina (Kaunas), 2023. 59(9). [
DOI:10.3390/medicina59091551] [
PMID] [
]
19. Greyson, B., Near-death experiences in a psychiatric outpatient clinic population. Psychiatric Services, 2003. 54(12): p. 1649-1651. [
DOI:10.1176/appi.ps.54.12.1649] [
PMID]